Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
Akeso builds on earlier success with bispecifics
Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.
